Get all your news in one place.
100's of premium titles.
One app.
Start reading
Medical Daily
Medical Daily
Cole Mercer

Eli Lilly's $2.75 Billion AI Bet on Anti-Aging Drugs Signals a Major Shift in Pharmaceutical Priorities

On March 29, 2026, the most valuable pharmaceutical company in the world made its largest-ever bet on artificial intelligence and aging.

Eli Lilly signed a drug discovery agreement with Insilico Medicine worth up to $2.75 billion, a Hong Kong-based, AI-driven biotechnology company that uses generative artificial intelligence to identify drug candidates targeting the biology of aging. The deal is not primarily about treating any one disease. It is about using AI to attack the underlying biological processes that make humans susceptible to dozens of age-related conditions at once.

Sign up to read this article
Read news from 100's of titles, curated specifically for you.
Already a member? Sign in here
Related Stories
Top stories on inkl right now
One subscription that gives you access to news from hundreds of sites
Already a member? Sign in here
Our Picks
Fourteen days free
Download the app
One app. One membership.
100+ trusted global sources.